Wells Fargo Starts Halozyme Therapeutics (HALO) at Equal Weight, 'Seven Reasons to Own HALO'
Tweet Send to a Friend
Wells Fargo analyst Mohit Bansal initiates coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Equal Weight rating and a price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
